-
1
-
-
77955635233
-
Cancer statistics
-
PID: 20610543
-
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073
-
(2010)
CA Cancer J Clin
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
COI: 1:CAS:528:DyaK2sXlsFKksLY%3D, PID: 9196156
-
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413
-
(1997)
J Clin Oncol
, vol.15
, Issue.6
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
Von Hoff, D.D.14
-
3
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
COI: 1:CAS:528:DC%2BD3cXisVynurk%3D, PID: 10766175
-
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886
-
(2000)
Cancer Res
, vol.60
, Issue.7
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kraling, B.M.3
Shi, B.4
Marshall, B.5
O’Reilly, M.S.6
Folkman, J.7
-
4
-
-
48749099984
-
Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study
-
COI: 1:CAS:528:DC%2BD1MXltVyiurs%3D, PID: 18691994
-
Andre N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC (2008) Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 30(7):1336–1340
-
(2008)
Clin Ther
, vol.30
, Issue.7
, pp. 1336-1340
-
-
Andre, N.1
Rome, A.2
Coze, C.3
Padovani, L.4
Pasquier, E.5
Camoin, L.6
Gentet, J.C.7
-
5
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
COI: 1:CAS:528:DC%2BD2cXksVaisbk%3D, PID: 15170445
-
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.6
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
6
-
-
0035865363
-
Redefining the target: chemotherapeutics as antiangiogenics
-
COI: 1:CAS:528:DC%2BD3MXhvFertrY%3D, PID: 11181686
-
Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19(4):1195–1206
-
(2001)
J Clin Oncol
, vol.19
, Issue.4
, pp. 1195-1206
-
-
Miller, K.D.1
Sweeney, C.J.2
Sledge, G.W.3
-
7
-
-
0036897097
-
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs
-
COI: 1:CAS:528:DC%2BD38XpsVahsLg%3D, PID: 12460910
-
Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23):6938–6943
-
(2002)
Cancer Res
, vol.62
, Issue.23
, pp. 6938-6943
-
-
Bocci, G.1
Nicolaou, K.C.2
Kerbel, R.S.3
-
8
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):15–24
-
(2000)
J Clin Invest
, vol.105
, Issue.8
, pp. 15-24
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.J.6
Bohlen, P.7
Kerbel, R.S.8
-
9
-
-
77954177848
-
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
-
COI: 1:CAS:528:DC%2BC3cXotFemsLk%3D, PID: 20531411
-
Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, Chang CW, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Yapp DT, Ng SS (2010) Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103(1):52–60. doi:10.1038/sj.bjc.6605727
-
(2010)
Br J Cancer
, vol.103
, Issue.1
, pp. 52-60
-
-
Cham, K.K.1
Baker, J.H.2
Takhar, K.S.3
Flexman, J.A.4
Wong, M.Q.5
Owen, D.A.6
Yung, A.7
Kozlowski, P.8
Reinsberg, S.A.9
Chu, E.M.10
Chang, C.W.11
Buczkowski, A.K.12
Chung, S.W.13
Scudamore, C.H.14
Minchinton, A.I.15
Yapp, D.T.16
Ng, S.S.17
-
10
-
-
77951932803
-
Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance
-
COI: 1:CAS:528:DC%2BC3cXkvVOjsLw%3D, PID: 20112275
-
Fuchs D, Rodriguez A, Eriksson S, Christofferson R, Sundberg C, Azarbayjani F (2010) Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int J Cancer 126(12):2773–2789. doi:10.1002/ijc.25206
-
(2010)
Int J Cancer
, vol.126
, Issue.12
, pp. 2773-2789
-
-
Fuchs, D.1
Rodriguez, A.2
Eriksson, S.3
Christofferson, R.4
Sundberg, C.5
Azarbayjani, F.6
-
11
-
-
84859395499
-
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis
-
COI: 1:CAS:528:DC%2BC38XjtlKis74%3D, PID: 22188817
-
Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS (2012) Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 11(3):680–689. doi:10.1158/1535-7163.mct-11-0659
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.3
, pp. 680-689
-
-
Francia, G.1
Shaked, Y.2
Hashimoto, K.3
Sun, J.4
Yin, M.5
Cesta, C.6
Xu, P.7
Man, S.8
Hackl, C.9
Stewart, J.10
Uhlik, M.11
Dantzig, A.H.12
Foster, F.S.13
Kerbel, R.S.14
-
12
-
-
0034792844
-
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice
-
COI: 1:CAS:528:DC%2BD3MXnvF2rs7k%3D, PID: 11595724
-
Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7(10):3269–3275
-
(2001)
Clin Cancer Res
, vol.7
, Issue.10
, pp. 3269-3275
-
-
Ng, S.S.1
Tsao, M.S.2
Nicklee, T.3
Hedley, D.W.4
-
13
-
-
0037058302
-
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice
-
COI: 1:CAS:528:DC%2BD38XotFSjtr4%3D, PID: 12385004
-
Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102(2):101–108. doi:10.1002/ijc.10681
-
(2002)
Int J Cancer
, vol.102
, Issue.2
, pp. 101-108
-
-
Bruns, C.J.1
Shrader, M.2
Harbison, M.T.3
Portera, C.4
Solorzano, C.C.5
Jauch, K.W.6
Hicklin, D.J.7
Radinsky, R.8
Ellis, L.M.9
-
14
-
-
0037093209
-
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
-
COI: 1:CAS:528:DC%2BD38XjvFSmsbg%3D, PID: 12019144
-
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62(10):2731–2735
-
(2002)
Cancer Res
, vol.62
, Issue.10
, pp. 2731-2735
-
-
Man, S.1
Bocci, G.2
Francia, G.3
Green, S.K.4
Jothy, S.5
Hanahan, D.6
Bohlen, P.7
Hicklin, D.J.8
Bergers, G.9
Kerbel, R.S.10
-
15
-
-
46849085176
-
Imaging and cancer: a review
-
PID: 19383333
-
Fass L (2008) Imaging and cancer: a review. Mol Oncol 2(2):115–152. doi:10.1016/j.molonc.2008.04.001
-
(2008)
Mol Oncol
, vol.2
, Issue.2
, pp. 115-152
-
-
Fass, L.1
-
16
-
-
2142641665
-
Clinical applications of PET in oncology
-
PID: 15044750
-
Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231(2):305–332. doi:10.1148/radiol.2312021185
-
(2004)
Radiology
, vol.231
, Issue.2
, pp. 305-332
-
-
Rohren, E.M.1
Turkington, T.G.2
Coleman, R.E.3
-
17
-
-
58149343907
-
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin
-
COI: 1:CAS:528:DC%2BD1cXhtlylur7P, PID: 19010842
-
Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, Yapp DT (2008) Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 14(22):7260–7271. doi:10.1158/1078-0432.CCR-08-0736
-
(2008)
Clin Cancer Res
, vol.14
, Issue.22
, pp. 7260-7271
-
-
Baker, J.H.1
Lam, J.2
Kyle, A.H.3
Sy, J.4
Oliver, T.5
Co, S.J.6
Dragowska, W.H.7
Ramsay, E.8
Anantha, M.9
Ruth, T.J.10
Adam, M.J.11
Yung, A.12
Kozlowski, P.13
Minchinton, A.I.14
Ng, S.S.15
Bally, M.B.16
Yapp, D.T.17
-
18
-
-
78649859816
-
Vascularization predicts overall survival and risk of transformation in follicular lymphoma
-
PID: 20713461
-
Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD (2010) Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 95(12):2157–2160. doi:10.3324/haematol.2009.021766
-
(2010)
Haematologica
, vol.95
, Issue.12
, pp. 2157-2160
-
-
Farinha, P.1
Kyle, A.H.2
Minchinton, A.I.3
Connors, J.M.4
Karsan, A.5
Gascoyne, R.D.6
-
19
-
-
36348998721
-
Fast, accurate, and precise mapping of the RF field in vivo using the 180 degrees signal null
-
PID: 17763355
-
Dowell NG, Tofts PS (2007) Fast, accurate, and precise mapping of the RF field in vivo using the 180 degrees signal null. Magn Reson Med 58(3):622–630. doi:10.1002/mrm.21368
-
(2007)
Magn Reson Med
, vol.58
, Issue.3
, pp. 622-630
-
-
Dowell, N.G.1
Tofts, P.S.2
-
20
-
-
20444455884
-
Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast
-
PID: 15950895
-
Armitage P, Behrenbruch C, Brady M, Moore N (2005) Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal 9(4):315–329. doi:10.1016/j.media.2005.01.001
-
(2005)
Med Image Anal
, vol.9
, Issue.4
, pp. 315-329
-
-
Armitage, P.1
Behrenbruch, C.2
Brady, M.3
Moore, N.4
-
21
-
-
42449143939
-
Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences
-
PID: 18421121
-
Schabel MC, Parker DL (2008) Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol 53(9):2345–2373. doi:10.1088/0031-9155/53/9/010
-
(2008)
Phys Med Biol
, vol.53
, Issue.9
, pp. 2345-2373
-
-
Schabel, M.C.1
Parker, D.L.2
-
22
-
-
0001609545
-
Theory of blood-tissue exchange and its applications to measurements of blood flow
-
Kety SS (1960) Theory of blood-tissue exchange and its applications to measurements of blood flow. Methods Med Res 8:223–227
-
(1960)
Methods Med Res
, vol.8
, pp. 223-227
-
-
Kety, S.S.1
-
23
-
-
0032828135
-
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols
-
COI: 1:STN:280:DyaK1Mvjsl2jtw%3D%3D, PID: 10508281
-
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):223–232
-
(1999)
J Magn Reson Imaging
, vol.10
, Issue.3
, pp. 223-232
-
-
Tofts, P.S.1
Brix, G.2
Buckley, D.L.3
Evelhoch, J.L.4
Henderson, E.5
Knopp, M.V.6
Larsson, H.B.7
Lee, T.Y.8
Mayr, N.A.9
Parker, G.J.10
Port, R.E.11
Taylor, J.12
Weisskoff, R.M.13
-
24
-
-
84961902687
-
Kozlowski P (2009) Parameter fits using measured population AIF vs. literature AIF in DCE-MRI of pancreatic cancer xenograft model
-
Yung AC, Tso JCH, Flexman JA, Ng SS, Yapp DT, Kozlowski P (2009) Parameter fits using measured population AIF vs. literature AIF in DCE-MRI of pancreatic cancer xenograft model. In: Proceedings of the international society for magnetic resonance in medicine 17th annual meeting: 2283
-
Proceedings of the international society for magnetic resonance in medicine 17th annual meeting
-
-
Yung, A.C.1
Tso, J.C.H.2
Flexman, J.A.3
Ng, S.S.4
Yapp, D.T.5
-
25
-
-
8844249275
-
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
-
PID: 15456718
-
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P (2003) Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 76(Spec No 1):S87–S91
-
(2003)
Br J Radiol
, vol.76
, Issue.Spec No 1
, pp. S87-S91
-
-
Leach, M.O.1
Brindle, K.M.2
Evelhoch, J.L.3
Griffiths, J.R.4
Horsman, M.R.5
Jackson, A.6
Jayson, G.7
Judson, I.R.8
Knopp, M.V.9
Maxwell, R.J.10
McIntyre, D.11
Padhani, A.R.12
Price, P.13
Rathbone, R.14
Rustin, G.15
Tofts, P.S.16
Tozer, G.M.17
Vennart, W.18
Waterton, J.C.19
Williams, S.R.20
Workman, P.21
more..
-
27
-
-
9144270641
-
Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges
-
PID: 15565801
-
Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23(5):65–83
-
(2004)
IEEE Eng Med Biol Mag
, vol.23
, Issue.5
, pp. 65-83
-
-
Collins, D.J.1
Padhani, A.R.2
-
28
-
-
0034798178
-
Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation
-
COI: 1:STN:280:DC%2BD3MrjvVOjsQ%3D%3D, PID: 11586098
-
Evans SM, Hahn SM, Magarelli DP, Koch CJ (2001) Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 24(5):467–472
-
(2001)
Am J Clin Oncol
, vol.24
, Issue.5
, pp. 467-472
-
-
Evans, S.M.1
Hahn, S.M.2
Magarelli, D.P.3
Koch, C.J.4
-
29
-
-
0028839715
-
Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity
-
COI: 1:CAS:528:DyaK2MXptlKjtLg%3D, PID: 7547233
-
Koch CJ, Evans SM, Lord EM (1995) Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72(4):869–874
-
(1995)
Br J Cancer
, vol.72
, Issue.4
, pp. 869-874
-
-
Koch, C.J.1
Evans, S.M.2
Lord, E.M.3
-
30
-
-
41649115595
-
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
-
COI: 1:CAS:528:DC%2BD1cXjtlWgsro%3D, PID: 18347150
-
Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, Galan M, Ribas IG, Germa JR, Capella G, Vinals F (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7(3):638–647. doi:10.1158/1535-7163.MCT-07-2122
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.3
, pp. 638-647
-
-
Laquente, B.1
Lacasa, C.2
Ginesta, M.M.3
Casanovas, O.4
Figueras, A.5
Galan, M.6
Ribas, I.G.7
Germa, J.R.8
Capella, G.9
Vinals, F.10
-
31
-
-
27644436870
-
The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
-
COI: 1:CAS:528:DC%2BD2MXht1WntrzO, PID: 15998832
-
Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben David Y, Kerbel RS (2005) The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058–3061
-
(2005)
Blood
, vol.106
, pp. 3058-3061
-
-
Shaked, Y.1
Emmenegger, U.2
Man, S.3
Cervi, D.4
Bertolini, F.5
Ben David, Y.6
Kerbel, R.S.7
-
32
-
-
84890287907
-
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
-
COI: 1:CAS:528:DC%2BC3sXhvVOitbzE, PID: 24088738
-
Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K (2013) A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19(23):6614–6623. doi:10.1158/1078-0432.CCR-13-1442
-
(2013)
Clin Cancer Res
, vol.19
, Issue.23
, pp. 6614-6623
-
-
Zhu, A.X.1
Finn, R.S.2
Mulcahy, M.3
Gurtler, J.4
Sun, W.5
Schwartz, J.D.6
Dalal, R.P.7
Joshi, A.8
Hozak, R.R.9
Xu, Y.10
Ancukiewicz, M.11
Jain, R.K.12
Nugent, F.W.13
Duda, D.G.14
Stuart, K.15
-
33
-
-
79960096827
-
Normalization of the vasculature for treatment of cancer and other diseases
-
COI: 1:CAS:528:DC%2BC3MXhtFyjurzO, PID: 21742796
-
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071–1121. doi:10.1152/physrev.00038.2010
-
(2011)
Physiol Rev
, vol.91
, Issue.3
, pp. 1071-1121
-
-
Goel, S.1
Duda, D.G.2
Xu, L.3
Munn, L.L.4
Boucher, Y.5
Fukumura, D.6
Jain, R.K.7
-
34
-
-
70350655979
-
VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy
-
COI: 1:CAS:528:DC%2BD1MXht1CrsL3F, PID: 19761418
-
Greenberg JI, Cheresh DA (2009) VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 9(11):1347–1356. doi:10.1517/14712590903208883
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.11
, pp. 1347-1356
-
-
Greenberg, J.I.1
Cheresh, D.A.2
-
35
-
-
11844254414
-
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
-
COI: 1:CAS:528:DC%2BD2MXnvFar, PID: 15637262
-
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62
-
(2005)
Science
, vol.307
, Issue.5706
, pp. 58-62
-
-
Jain, R.K.1
-
36
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
COI: 1:CAS:528:DC%2BD1cXovV2lsrk%3D, PID: 18650835
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603. doi:10.1038/nrc2442
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
37
-
-
77955887676
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
-
COI: 1:CAS:528:DC%2BC3cXhtFSksb3I, PID: 20606091
-
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22):3617–3622. doi:10.1200/jco.2010.28.1386
-
(2010)
J Clin Oncol
, vol.28
, Issue.22
, pp. 3617-3622
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
Sutherland, S.4
Schrag, D.5
Hurwitz, H.6
Innocenti, F.7
Mulcahy, M.F.8
O’Reilly, E.9
Wozniak, T.F.10
Picus, J.11
Bhargava, P.12
Mayer, R.J.13
Schilsky, R.L.14
Goldberg, R.M.15
-
38
-
-
40749120515
-
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy
-
COI: 1:CAS:528:DC%2BD1cXoslKg, PID: 18172279
-
Blansfield JA, Caragacianu D, Alexander HR, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14(1):270–280. doi:10.1158/1078-0432.ccr-07-1562
-
(2008)
Clin Cancer Res
, vol.14
, Issue.1
, pp. 270-280
-
-
Blansfield, J.A.1
Caragacianu, D.2
Alexander, H.R.3
Tangrea, M.A.4
Morita, S.Y.5
Lorang, D.6
Schafer, P.7
Muller, G.8
Stirling, D.9
Royal, R.E.10
Libutti, S.K.11
-
39
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
COI: 1:STN:280:DC%2BD3c7it1Gitg%3D%3D, PID: 10655437
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
40
-
-
33749029255
-
Sometimes size doesn’t matter: reevaluating RECIST and tumor response rate endpoints
-
PID: 16985244
-
Tuma RS (2006) Sometimes size doesn’t matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 98(18):1272–1274. doi:10.1093/jnci/djj403
-
(2006)
J Natl Cancer Inst
, vol.98
, Issue.18
, pp. 1272-1274
-
-
Tuma, R.S.1
-
41
-
-
33646357786
-
Measuring response in a post-RECIST world: from black and white to shades of grey
-
COI: 1:CAS:528:DC%2BD28XjslGitbo%3D, PID: 16633367
-
Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6(5):409–414. doi:10.1038/nrc1883
-
(2006)
Nat Rev Cancer
, vol.6
, Issue.5
, pp. 409-414
-
-
Michaelis, L.C.1
Ratain, M.J.2
-
42
-
-
13944279944
-
Monitoring response to treatment in patients utilizing PET
-
PID: 15693656
-
Avril NE, Weber WA (2005) Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43(1):189–204
-
(2005)
Radiol Clin North Am
, vol.43
, Issue.1
, pp. 189-204
-
-
Avril, N.E.1
Weber, W.A.2
-
43
-
-
67349207407
-
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy
-
COI: 1:CAS:528:DC%2BD1MXmtlOqtr4%3D, PID: 19136215
-
Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT (2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35(4):309–321. doi:10.1016/j.ctrv.2008.12.001
-
(2009)
Cancer Treat Rev
, vol.35
, Issue.4
, pp. 309-321
-
-
Desar, I.M.1
van Herpen, C.M.2
van Laarhoven, H.W.3
Barentsz, J.O.4
Oyen, W.J.5
van der Graaf, W.T.6
-
44
-
-
77956862485
-
New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
-
PID: 20729419
-
Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Janne PA, Johnson BE, Van den Abbeele AD (2010) New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 195(3):W221–W228. doi:10.2214/ajr.09.3928
-
(2010)
AJR Am J Roentgenol
, vol.195
, Issue.3
, pp. W221-W228
-
-
Nishino, M.1
Jackman, D.M.2
Hatabu, H.3
Yeap, B.Y.4
Cioffredi, L.A.5
Yap, J.T.6
Janne, P.A.7
Johnson, B.E.8
Van den Abbeele, A.D.9
-
45
-
-
77749237123
-
FDG PET/CT in the detection of recurrent rectal cancer
-
PID: 20302028
-
Kau T, Reinprecht P, Eicher W, Lind P, Starlinger M, Hausegger KA (2009) FDG PET/CT in the detection of recurrent rectal cancer. Int Surg 94(4):315–324
-
(2009)
Int Surg
, vol.94
, Issue.4
, pp. 315-324
-
-
Kau, T.1
Reinprecht, P.2
Eicher, W.3
Lind, P.4
Starlinger, M.5
Hausegger, K.A.6
-
46
-
-
73449129694
-
A Prospective Diagnostic Accuracy Study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer
-
PID: 19687736
-
Kauhanen SP, Komar G, Seppanen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT (2009) A Prospective Diagnostic Accuracy Study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. doi:10.1097/SLA.0b013e3181b2fafa
-
(2009)
Ann Surg
-
-
Kauhanen, S.P.1
Komar, G.2
Seppanen, M.P.3
Dean, K.I.4
Minn, H.R.5
Kajander, S.A.6
Rinta-Kiikka, I.7
Alanen, K.8
Borra, R.J.9
Puolakkainen, P.A.10
Nuutila, P.11
Ovaska, J.T.12
-
47
-
-
77956182982
-
Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET
-
COI: 1:CAS:528:DC%2BC3cXpvVyqtbo%3D, PID: 20461370
-
Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, Mortelmans L, Mottaghy FM (2010) Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 37(9):1688–1695. doi:10.1007/s00259-010-1479-0
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, Issue.9
, pp. 1688-1695
-
-
Brepoels, L.1
De Saint-Hubert, M.2
Stroobants, S.3
Verhoef, G.4
Balzarini, J.5
Mortelmans, L.6
Mottaghy, F.M.7
-
48
-
-
78449288666
-
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
-
COI: 1:CAS:528:DC%2BC3cXhtlant77F, PID: 20446016
-
Stockhammer F, Misch M, Koch A, Czabanka M, Plotkin M, Blechschmidt C, Tuettenberg J, Vajkoczy P (2010) Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100(3):407–415. doi:10.1007/s11060-010-0192-y
-
(2010)
J Neurooncol
, vol.100
, Issue.3
, pp. 407-415
-
-
Stockhammer, F.1
Misch, M.2
Koch, A.3
Czabanka, M.4
Plotkin, M.5
Blechschmidt, C.6
Tuettenberg, J.7
Vajkoczy, P.8
-
49
-
-
84929312425
-
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: rational and current status
-
PID: 25414818
-
Digklia A, Voutsadakis IA (2014) Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: rational and current status. World J Exp Med 4(4):58–67
-
(2014)
World J Exp Med
, vol.4
, Issue.4
, pp. 58-67
-
-
Digklia, A.1
Voutsadakis, I.A.2
-
50
-
-
84885174214
-
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
-
COI: 1:CAS:528:DC%2BC3sXhsVGjsr7M, PID: 24022191
-
Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK (2013) A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer 109(7):1725–1734. doi:10.1038/bjc.2013.553
-
(2013)
Br J Cancer
, vol.109
, Issue.7
, pp. 1725-1734
-
-
Kelley, R.K.1
Hwang, J.2
Magbanua, M.J.3
Watt, L.4
Beumer, J.H.5
Christner, S.M.6
Baruchel, S.7
Wu, B.8
Fong, L.9
Yeh, B.M.10
Moore, A.P.11
Ko, A.H.12
Korn, W.M.13
Rajpal, S.14
Park, J.W.15
Tempero, M.A.16
Venook, A.P.17
Bergsland, E.K.18
-
51
-
-
57749092182
-
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
-
COI: 1:CAS:528:DC%2BD1cXhsV2iurnN, PID: 19074844
-
Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7(12):3670–3684. doi:10.1158/1535-7163.MCT-08-0715
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.12
, pp. 3670-3684
-
-
Ma, J.1
Waxman, D.J.2
-
52
-
-
84946560035
-
From palliative to curative treatment-stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery—a case report
-
PID: 26555668
-
Vernmark K, Albertsson M, Bjornsson B, Gasslander T, Sandstrom P, Sun XF, Holmqvist A (2015) From palliative to curative treatment-stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery—a case report. BMC Cancer 15:884. doi:10.1186/s12885-015-1908-3
-
(2015)
BMC Cancer
, vol.15
, pp. 884
-
-
Vernmark, K.1
Albertsson, M.2
Bjornsson, B.3
Gasslander, T.4
Sandstrom, P.5
Sun, X.F.6
Holmqvist, A.7
-
53
-
-
77954595880
-
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer
-
PID: 20606044
-
Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH (2010) Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9(7):2068–2078. doi:10.1158/1535-7163.MCT-10-0201
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.7
, pp. 2068-2078
-
-
Tran Cao, H.S.1
Bouvet, M.2
Kaushal, S.3
Keleman, A.4
Romney, E.5
Kim, G.6
Fruehauf, J.7
Imagawa, D.K.8
Hoffman, R.M.9
Katz, M.H.10
-
54
-
-
0036152447
-
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts
-
COI: 1:CAS:528:DC%2BD38XhsVKlsrs%3D, PID: 11801563
-
Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8(1):221–232
-
(2002)
Clin Cancer Res
, vol.8
, Issue.1
, pp. 221-232
-
-
Klement, G.1
Huang, P.2
Mayer, B.3
Green, S.K.4
Man, S.5
Bohlen, P.6
Hicklin, D.7
Kerbel, R.S.8
-
55
-
-
79958054297
-
Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance
-
COI: 1:CAS:528:DC%2BC3MXos1KgtrY%3D, PID: 22977546
-
Murakami H, Ogata Y, Akagi Y, Ishibashi N, Shirouzu K (2011) Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance. Exp Ther Med 2(4):595–600. doi:10.3892/etm.2011.253
-
(2011)
Exp Ther Med
, vol.2
, Issue.4
, pp. 595-600
-
-
Murakami, H.1
Ogata, Y.2
Akagi, Y.3
Ishibashi, N.4
Shirouzu, K.5
-
56
-
-
33947191055
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
-
COI: 1:CAS:528:DC%2BD2sXhvF2htr8%3D, PID: 17317837
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi:10.1158/1078-0432.CCR-06-2309
-
(2007)
Clin Cancer Res
, vol.13
, Issue.4
, pp. 1253-1259
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon, J.E.3
Dowell, J.M.4
Reardon, D.A.5
Quinn, J.A.6
Rich, J.N.7
Sathornsumetee, S.8
Gururangan, S.9
Wagner, M.10
Bigner, D.D.11
Friedman, A.H.12
Friedman, H.S.13
-
57
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
COI: 1:CAS:528:DC%2BD2sXhtlCgsLjF, PID: 17947719
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi:10.1200/JCO.2007.12.2440
-
(2007)
J Clin Oncol
, vol.25
, Issue.30
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon, J.E.3
Marcello, J.4
Reardon, D.A.5
Quinn, J.A.6
Rich, J.N.7
Sathornsumetee, S.8
Gururangan, S.9
Sampson, J.10
Wagner, M.11
Bailey, L.12
Bigner, D.D.13
Friedman, A.H.14
Friedman, H.S.15
-
58
-
-
54449099774
-
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
-
COI: 1:CAS:528:DC%2BD1cXhtlGitrzI, PID: 18794539
-
Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899–4905. doi:10.1200/JCO.2008.17.4789
-
(2008)
J Clin Oncol
, vol.26
, Issue.30
, pp. 4899-4905
-
-
Dellapasqua, S.1
Bertolini, F.2
Bagnardi, V.3
Campagnoli, E.4
Scarano, E.5
Torrisi, R.6
Shaked, Y.7
Mancuso, P.8
Goldhirsch, A.9
Rocca, A.10
Pietri, E.11
Colleoni, M.12
|